

Comparison of Peak Serum C-Reactive Protein and Hydroxybutyrate Dehydrogenase Levels in Patients With Acute Myocardial Infarction Treated With Alteplase and Streptokinase

Kari Pietilä, MD, Wim T. Hermens, PhD, Aimo Harmoinen, MS, Taco Baardman, MD, Amos Pasternack, MD, Eric J. Topol, MD, and Maarten L. Simoons, MD

Acute myocardial infarction (AMI) is associated with an acute-phase inflammatory reaction measurable by determination of serum C-reactive protein.¹⁻⁵ The highest serum C-reactive protein values correlate with the size of the AMI when thrombolytic treatment is not given.³ If reperfusion by thrombolytic treatment occurs in AMI, the serum C-reactive protein values are lower than would be expected according to infarct size.³⁻⁵ These low serum C-reactive protein values are associated with a favorable survival prognosis during the first 6 months after AMI.⁶ In this study we investigate the infarct-related acute-phase reaction after treatment with accelerated alteplase, streptokinase, or a combination of both. We also wanted to elucidate whether the Thrombolysis in Myocardial Infarction (TIMI) patency grade of the infarct-related artery⁷ was associated with this acute-phase reaction.

...

We studied patients who had been randomized to undergo early (90 minute) coronary angiography in the Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries (GUSTO-I) enzyme substudy.⁸ Overall, 174 patients from the 553 patients in the enzyme substudy had been randomly assigned to angiography at the centers that also participated in the GUSTO-I angiographic substudy.⁹ Because the GUSTO-I main trial¹⁰ was unable to show any survival difference between the 2 streptokinase monotherapies, we chose to combine these groups. Accordingly, in this study we compared 3 treatment groups: (1) the accelerated alteplase group, (2) the streptokinase groups, and (3) the combination treatment group.

Blood samples were available from 146 patients, 48 of whom had been treated with alteplase, 66 with streptokinase, and 32 with the combination of streptokinase and alteplase. Blood samples for the study were drawn at the start of thrombolytic treatment and 1, 3, 5, 12, 18, 24, 36, 48, 72, and 96 hours later. They were analyzed for C-reactive protein and hydroxybu-

	Alteplase (n = 48)	Streptokinase (n = 63)	Combined Alteplase- Streptokinase (n = 32)
Age (yr ± SD)	59 ± 12	61 ± 12	60 ± 11
Women (%)	9 (18%)	19 (30%)	3 (9%)
Time from chest pain onset to start of thrombolysis (hours ± SD)	3.5 ± 1.9	3.5 ± 2.2	3.5 ± 4.7
Time from the beginning of the treatment to angiography (minute ± SD)	96 ± 9	97 ± 10	97 ± 9
Infarct location (%)			
Anterior	24 (50%)	23 (37%)	21 (66%)
Inferior	22 (46%)	35 (55%)	10 (31%)
Other	2 (4%)	5 (8%)	1 (3%)

tyrate dehydrogenase as described.^{11,12} The size of the AMI was determined from the cumulative release of hydroxybutyrate lactate dehydrogenase.¹² In 143 of the patients all 11 blood samples were available for analysis. In 3 patients the highest serum C-reactive protein could not be determined with certainty because of death within the first 2 days. These 3 patients were all in the streptokinase group and are not included in the final analyses.

Coronary angiography was performed in all patients 90 minutes after the start of the thrombolytic therapy. The angiographic patency of the infarct-related coronary artery was graded from 0 to 3 using the TIMI classifications.⁷

Continuous variables were summarized in terms of means ± SD and categorical variables by percentages. Multivariate analysis, the Student's *t* test and chi-square test were used in statistical analyses. These were determined with the Statgraphics Plus for Windows (Version 2.0; Manugistics Inc., Rockville, Maryland) statistical package.

...

At randomization the patients in alteplase, streptokinase, and alteplase and streptokinase treatment groups did not differ with respect to age, delay from the onset of chest pain to the start of the treatment, time from the beginning of the treatment to angiography, or infarct location (Table I).

Highest serum C-reactive protein concentrations were reached 36 to 96 hours after AMI. The serum C-reactive protein concentrations were lower overall in

From the Clinic of Internal Medicine, Department of Clinical Sciences; and the Department of Clinical Chemistry, Tampere University, Tampere, Finland; the Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; Thoraxcenter, Erasmus University, Rotterdam, The Netherlands; and the Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio. This study was supported by a grant from the Finnish Heart Association, Helsinki, Finland. Dr. Pietilä's address is: Clinic of Internal Medicine, Tampere University Hospital, P.O. Box 2000, FIN-335210 Tampere, Finland. Manuscript received February 4, 1997; revised manuscript received and accepted June 18, 1997.




FIGURE 1. Serum C-reactive protein concentration after myocardial infarction in different treatment groups. *A*, serum C-reactive protein as a function of time after the infarction (means and 95% confidence intervals for the means). *B*, highest serum C-reactive protein concentrations (means and 95% confidence intervals for the means). The existence of significant differences between the groups was discovered by the analysis of variance method; significant differences were restudied by Student's *t* test to obtain the exact *p* values.




FIGURE 2. Highest serum C-reactive protein concentrations in patients with TIMI grade 0 to 2 and TIMI grade 3 blood flow in the infarct-related coronary artery (means and 95% confidence intervals of the means). The statistical significance was calculated by Student's *t* test. Open bar, TIMI 0 to 2 flow in the infarct-related coronary artery. Lined bar, TIMI 3 flow in the infarct-related coronary artery.

the alteplase group than in the streptokinase and combination treatment groups, as were the peak serum concentrations (Figure 1). There was a tendency toward smaller infarcts in the alteplase-treated patients than in the strep-

tokinase-treated patients, but the difference was not statistically significant. The cumulative amounts of hydroxybutyrate dehydrogenase released were 4.51 ± 3.17 , 5.61 ± 3.56 , and 4.47 ± 3.92 g-Eq/L in the alteplase, streptokinase, and combination treatment groups, respectively.

The peak C-reactive protein values were lower in patients who had TIMI grade 3 perfusion in the infarct-related coronary artery than in those with TIMI grade 0 to 2 flow (Figure 2). When the patients who had TIMI grade 0 to 2 flow were further divided into grade 2 versus grade 0 to 1 flow, the peak C-reactive protein values did not differ between these groups (82 ± 67 and 75 ± 58 mg/L). According to multivariate analysis, the peak C-reactive protein values of the patients who had TIMI grade 3 flow differed significantly ($p = 0.020$) from those of patients who had TIMI grade 2 flow, whereas the difference between patients who had grade 2 flow versus grade 0 to 1 flow did not quite reach statistical significance ($p = 0.074$). Patients who had TIMI grade 3 flow had smaller enzyme release than those who had grade 0 to 2 flow (4.0 ± 3.2 and 5.6 ± 3.7 g-Eq/L hydroxybutyrate dehydrogenase released; $p = 0.008$).

Among patients who died during hospitalization for whom a reliable peak serum C-reactive protein concentration could be determined, values were higher among those who survived (143 ± 122 vs 70 ± 54 mg/L; $p < 0.01$). There were only 8 deaths in the study, however, and in only 5 of these patients was a reliable peak value of serum C-reactive protein available.

...

This study shows that treatment of AMI with accelerated dosing of alteplase leads to a smaller acute-phase reaction than does streptokinase treatment alone or combination treatment with streptokinase and alteplase. In the GUSTO-I enzyme substudy, Baardman et al⁸ showed that treatment with alteplase led to smaller infarcts, as determined from the release of hydroxybutyrate dehydrogenase, than did treatment with streptokinase. In the present subset of their patients, there was only a trend toward smaller infarcts in the alteplase-treated patients compared with other patients. A smaller sample size probably explains why we could not detect a significant difference. This finding is further supported by our finding that, in accordance with the main study, there was a significant association between infarct size and the TIMI flow grade in the infarct-related artery. However, our earlier studies^{3,5} have shown that in patients who undergo thrombolysis for myocardial infarction, the patency of the infarct-related artery affects the serum C-reactive protein values independent of its effect on infarct size. In this study, the lower peak C-reactive protein values

were significantly associated with complete reperfusion (TIMI grade 3 flow) in the infarct-related coronary artery. It thus seems that the better early patency of the infarct-related artery obtained with alteplase compared with streptokinase or the combination treatment¹³ reduces the associated acute-phase reaction.

It has been shown that the patients with TIMI grade 3 flow in the infarct-related artery have a favorable survival prognosis.^{13,14} We have shown that patients who undergo thrombolysis for AMI and whose serum C-reactive protein values remain low have a decreased risk of death than those whose values increase over time.⁶ We did not specifically examine the relation of the peak serum C-reactive protein value and early mortality in this study; nevertheless, patients who died during hospitalization and in whom the peak serum C-reactive protein value could be reliably determined had higher values than those who survived.

In conclusion, thrombolytic treatment of AMI with accelerated alteplase is associated with lower peak serum C-reactive protein values than treatment with either streptokinase or a combination of streptokinase and alteplase. The low-peak serum C-reactive protein values were associated with complete reperfusion of the infarct-related coronary artery. Thus, the more efficient reperfusion with alteplase compared with the other regimens¹³ may reduce the inflammatory reaction of AMI.

Acknowledgment: The authors wish to thank the GUSTO-I Steering Committee for their review of the manuscript and Pat Williams for editorial comments.

1. de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein in myocardial ischaemia and infarction. *Br Heart J* 1982;47:239-243.

2. Pepys MB. C-reactive protein fifty years on. *Lancet* 1981;1:653-657.

3. Pietilä K, Harmoinen A, Pöyhönen L, Koskinen M, Heikkilä J, Ruosteenoja R. Intravenous streptokinase treatment and serum C-reactive protein in patients with acute myocardial infarction. *Br Heart J* 1987;58:225-229.

4. Pietilä K, Harmoinen A, Teppo AM. Acute phase reaction, infarct size and in-hospital morbidity in myocardial infarction patients treated with streptokinase or recombinant type plasminogen activator. *Ann Med* 1991;23:529-535.

5. Pietilä K, Harmoinen A, Hermens W, Simoons ML, Van de Werf F, Verstraete M. Serum C-reactive protein and infarct size in myocardial infarction patients with a closed versus an open infarct related coronary artery after thrombolytic therapy. *Eur Heart J* 1993;14:915-919.

6. Pietilä K, Harmoinen A, Jokiniitty J, Pasternack A. Serum C-reactive protein concentration in acute myocardial infarction and its relation to mortality during 24 months of follow-up in patients under thrombolytic treatment. *Eur Heart J* 1996;17:1345-1349.

7. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P et al. Thrombolysis in myocardial infarction (TIMI) trial, Phase I: a comparison between intravenous tissue type plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. *Circulation* 1987;76:142-154.

8. Baardman T, Hermens WT, Lenderink T, Molhoek GP, Grollier G, Pfisterer M, Simoons ML. Differential effects of tissue plasminogen activator and streptokinase on infarct size and rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy. *Eur Heart J* 1996;17:237-246.

9. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase or both on coronary-artery patency, ventricular function and survival after acute myocardial infarction. *N Engl J Med* 1993;329:1615-1622.

10. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. *N Engl J Med* 1993;329:673-682.

11. Harmoinen A. Immunoassay of C-reactive protein using the Hitachi 705E analyzer. *J Clin Chem Biochem* 1985;23:45-46.

12. van der Laarse A, Hermens WT, Hollaar L. Assessment of myocardial damage in patients with acute myocardial infarction by serial measurements of serum alpha-hydroxybutyrate dehydrogenase levels. *Am Heart J* 1984;107:248-260.

13. Simes RJ, Topol EJ, Holmes DR Jr, White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D, Betriu A, Califf RM, Ross AM, for the GUSTO-I Investigators. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery patency. *Circulation* 1995;91:1923-1928.

14. Lenderink T, Simoons ML, Van Es GA, Van de Werf F, Verstraete M, Arnold AE, for the European Cooperative Study Group. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. *Circulation* 1995;92:1110-1116.

Clinical and Angiographic Implications of Balloon Rupture During Coronary Stenting

Fernando Alfonso, MD, María J. Pérez-Vizcayno, MD, Rosana Hernández, MD, Javier Goicolea, MD, Antonio Fernández-Ortiz, MD, Camino Bañuelos, MD, and Carlos Macaya, MD

Coronary stenting is increasingly being used during percutaneous coronary interventions.¹⁻³ This technique is currently selected not only for patients with suboptimal results or complications after balloon dilation, but also electively, in an attempt to reduce the restenosis rate.^{1,2} In the early days, coronary stenting was flawed by a relatively high incidence of subacute

stent thrombosis and the requirement for prolonged anticoagulation, with its associated bleeding complications.¹ Today, these 2 important limitations have been mostly overcome by improvements in stent implantation techniques.³ Intravascular ultrasound studies frequently demonstrate inadequate stent deployment (incomplete expansion, suboptimal apposition, or stent asymmetry) even in patients with excellent angiographic results, and that high inflation pressures may help to optimize the implantation of these devices.³ This new strategy, namely, using relatively high pressures in conjunction with a simple regimen of antiplatelet therapy, has been associated with ex-

From the Interventional Cardiology Unit, San Carlos University Hospital, Madrid, Spain. Dr. Alfonso's address is: Unidad de Hemodinámica y Cardiología Intervencionista, Departamento Cardiopulmonar, Hospital Universitario "San Carlos," Ciudad Universitaria, Plaza de Cristo Rey, Madrid 28040, Spain. Manuscript received April 13, 1997; revised manuscript received and accepted June 19, 1997.